Another study revealed that a combination of flutamide and phenprocoumon, which target androgen receptors and vitamin K, respectively, showed synergistic synthetic lethal effects on androgen receptor-positive chronic myeloid leukemia and prostate cancer cells [13]. The gene discussed is AR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.